Neoadjuvant endocrine therapy has traditionally been limited to a minority of patients; nevertheless, interest in the activity of CDK4/6 inhibitors in early breast cancer prompted the initiation of four RCTs. This evidence concerns the gene CDK4 and breast carcinoma.